Related Experiment Video
Updated: Aug 13, 2026
04:41
Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
Published on: March 10, 2023
Hepatoblastoma: an oncological review
Derek J Roebuck1, Giorgio Perilongo
1Department of Radiology, Great Ormond Street Hospital, London, WC1N 3JH, UK. roebud@gosh.nhs.uk
Pediatric Radiology
|January 13, 2006
Summary
Pediatric hepatoblastoma survival rates have significantly improved, now exceeding 70% due to advancements in surgical techniques and chemotherapy. Future research aims to enhance outcomes for high-risk cases and reduce treatment-related side effects.
Area of Science:
- Pediatric Oncology
- Hepatoblastoma Research
- Cancer Treatment Advances
Background:
- Hepatoblastoma, a rare childhood liver cancer, historically had a poor prognosis.
- Significant progress in pediatric oncology has transformed hepatoblastoma outcomes.
- Current 5-year survival rates for hepatoblastoma now exceed 70%.
Purpose of the Study:
- To highlight the advancements in hepatoblastoma treatment.
- To acknowledge the impact of surgical and chemotherapeutic innovations.
- To outline future directions for improving high-risk tumor survival and reducing treatment morbidity.
Main Methods:
- Review of historical and current treatment protocols for hepatoblastoma.
- Analysis of survival data reflecting treatment efficacy.
- Identification of key factors contributing to improved outcomes.
Main Results:
- A dramatic increase in 5-year survival rates for hepatoblastoma patients, surpassing 70%.
- Surgical advancements and chemotherapy regimens are primary drivers of improved prognosis.
- Established effective treatment strategies for the majority of hepatoblastoma cases.
Conclusions:
- Hepatoblastoma treatment exemplifies successful progress in pediatric cancer care.
- Future efforts should focus on optimizing treatment for high-risk pediatric liver cancer.
- Reducing treatment-related morbidity remains a critical goal for improving quality of life in survivors.
